|
May 27
|
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
|
|
May 16
|
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
May 13
|
EyePoint Announces Participation at Upcoming Investor Conferences
|
|
Mar 6
|
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k
|
|
Mar 6
|
Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call
|
|
Mar 6
|
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ...
|
|
Jan 30
|
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
|
|
Jan 25
|
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss
|